UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Rhythm Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

76243J105 (CUSIP Number)

February 1, 2024 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 76243J105

1	NAMES OF REPORTING PERSONS						
	Perceptive A	Perceptive Advisors LLC					
2							
	(a)						
3	SEC USE ONLY						
3	SEC USE UNLI						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
Delaware							
		5	SOLE VOTING POWER				
N.	LIMDED OF						
IN	NUMBER OF SHARES		SHARED VOTING POWER				
	NEFICIALLY						
C	OWNED BY		3,260,013				
R	EACH EPORTING	7	SOLE DISPOSITIVE POWER				
1	PERSON		0				
	WITH:	8	SHARED DISPOSITIVE POWER				
0	A CODEC AT	TF A	3,260,013 MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	AGGREGAI	EA	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	3,260,013						
10		X IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
	_						
11	DEDCENT	NE C	LACC DEDUCCENTED BY AMOUNT IN DOWN				
11	PEKCENT (JF C	LASS REPRESENTED BY AMOUNT IN ROW 9				
	5.5%						
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
	IA						

CUSIP No. 76243J105

1	NAMES OF REPORTING PERSONS						
	Joseph Edelman						
2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)						
	(a) □ (b) □						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	United States		* **				
		5	SOLE VOTING POWER				
N	UMBER OF		0				
	SHARES	6	SHARED VOTING POWER				
	BENEFICIALLY		2.2(0.012				
C	OWNED BY EACH	7	3,260,013 SOLE DISPOSITIVE POWER				
R	EACH EPORTING	/	SOLE DISPOSITIVE POWER				
PERSON			0				
	WITH:	8	SHARED DISPOSITIVE POWER				
		0	SHARED DISTOSITIVE FOWER				
			3,260,013				
9	AGGREGAT	ΈA	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	3,260,013						
10	CHECK BO	X IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9						
	5.5%						
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
	IN						

CUSIP No. 76243J105

1	NAMES OF REPORTING PERSONS							
	Perceptive L	Perceptive Life Sciences Master Fund, Ltd.						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)							
	(a) (b) (c)							
3	3 SEC USE ONLY							
4	CITIZENSHIP OR PLACE OF ORGANIZATION							
	Cayman Islan	nds						
		5	SOLE VOTING POWER					
N	UMBER OF		0					
	SHARES	6	SHARED VOTING POWER					
	NEFICIALLY							
C	WNED BY		3,260,013					
	EACH	7	SOLE DISPOSITIVE POWER					
K	EPORTING							
	PERSON WITH:		0					
	VV 1111.	8	SHARED DISPOSITIVE POWER					
			2.2(0.012					
	A CCDEC AT	T A	3,260,013 MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
9	AGGREGAI	ΕA	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	3,260,013							
10								
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)							
11		F C	LASS REPRESENTED BY AMOUNT IN ROW 9					
		-						
	5.5%							
12								
	СО							

Item 1(a). Name of Issuer:

Rhythm Pharmaceuticals, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

222 Berkely Street, 12th Floor Boston, MA 02116

Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the "Reporting Persons") are:

Perceptive Advisors LLC ("Perceptive Advisors")
Joseph Edelman ("Mr. Edelman")
Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor New York, NY 10003

Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation

Item 2(d). <u>Title of Class of Securities</u>:

Common stock, \$0.001 par value per share ("Common Stock")

Item 2(e). <u>CUSIP Number</u>:

76243J105

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on an aggregate of 59,096,454 shares of Common Stock outstanding as of November 1, 2023, as reported by the Issuer in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

The Master Fund directly holds 3,260,013 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own shares held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the shares held by the Master Fund.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.</u>

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. <u>Notice of Dissolution of Group.</u>

Not applicable.

Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 12, 2024

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: February 12, 2024

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member